BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25521401)

  • 21. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
    Nishio M; Yamanaka T; Matsumoto K; Kimura H; Sakai K; Sakai A; Sone T; Horiike A; Koizumi F; Kasahara K; Ohira T; Ikeda N; Saijo N; Arao T; Nishio K
    J Thorac Oncol; 2011 Nov; 6(11):1889-94. PubMed ID: 21964526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.
    Kenmotsu H; Naito T; Mori K; Ko R; Ono A; Wakuda K; Imai H; Taira T; Murakami H; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):521-6. PubMed ID: 25563718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
    Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM
    Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
    Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
    Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
    Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and Clinical Significance of Cytokeratin-19 and Thymidine Kinase-1 in Advanced Gastrointestinal Cancer.
    Du YY; Zhang QJ; Sun GP
    Chin Med J (Engl); 2016 Sep; 129(18):2168-72. PubMed ID: 27625087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
    Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
    Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling.
    Mao Y; Wu J; Skog S; Eriksson S; Zhao Y; Zhou J; He Q
    Oncol Rep; 2005 May; 13(5):837-46. PubMed ID: 15809747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.
    Jagarlamudi KK; Moreau L; Westberg S; Rönnberg H; Eriksson S
    PLoS One; 2015; 10(9):e0137871. PubMed ID: 26366881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
    Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
    Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
    Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
    Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.